PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Cosentyx (secukinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. What diagnosis is this drug being prescribed for (pick one)?

- ☐ Plaque Psoriasis
- ☐ Psoriatic Arthritis
- ☐ Ankylosing Spondylitis
- ☐ Other

Q2. Please provide ICD code for diagnosis.

Q3. Please indicate location of administration.

- ☐ Home
- ☐ Long Term Care (LTC) facility
- ☐ Physician office (drug from office stock)
- ☐ Physician office (drug from pharmacy with a prescription)

Q4. Is the patient a NEW START to the requested medication?

☐ Yes ☐ No

Q5. Is the prescriber a Dermatologist?

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Cosentyx (secukinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

☐ Yes ☐ No

Q6. Is the prescriber a Rheumatologist?

☐ Yes ☐ No

Q7. If requested indication is plaque psoriasis, does the patient have moderate to severe plaque psoriasis affecting greater than 5% of body surface area (BSA)?

☐ Yes ☐ No

Q8. If request is for plaque psoriasis, does the patient have moderate to severe plaque psoriasis affecting crucial body areas such as hands, feet, face, or genitals?

☐ Yes ☐ No

Q9. If request is for plaque psoriasis, has the patient failed an adequate trial of at least TWO TOPICAL treatments [including but not limited to corticosteroids, Vitamin D analogues, Vitamin D analogue/corticosteroid combinations, Tazorac® (tazarotene)]?

☐ Yes ☐ No

Q10. If request is for plaque psoriasis, has the patient failed an adequate trial or does the patient have a contraindication to phototherapy (UVB or PUVA)?

☐ Yes ☐ No

Q11. If request is for plaque psoriasis, has the patient failed an adequate trial of at least one or contraindication(s) to methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, and tacrolimus?

☐ Yes ☐ No

Q12. If request is for psoriatic arthritis or ankylosing spondylitis, does patient have documented spinal involvement?

☐ Yes ☐ No

Q13. If request is for psoriatic arthritis, has patient failed an adequate trial of methotrexate (MTX)?

☐ Yes ☐ No

Q14. If request is for psoriatic arthritis, does the patient have a contraindication to methotrexate (MTX)?

☐ Yes (Please specify)

☐ No

Q15. If patient has a contraindication to methotrexate, has patient failed at least one other DMARD (hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, D-penicillamine, gold, minocycline, cyclosporine)?

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Cosentyx (secukinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

☐ Yes ☐ No

Q16. If request is for ankylosing spondylitis, has patient failed an adequate trial of or does the patient have a contraindication to NSAIDs?

☐ Yes (Please list NSAIDS tried)
☐ No

Q17. Has the patient failed an adequate trial of, clinically significant intolerance to, or contraindication to at least one preferred formulary biologic agent FDA approved for treatment of plaque psoriasis: Enbrel and Humira? (Please Specify which agents patient has failed)

☐ No
☐ Enbrel
☐ Humira
☐ Other - please specify

Q18. Additional comments

Prescriber Signature

Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Cosentyx (secukinumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**